Clinical trials: Attention-Deficit and Hyperactivity Disorder
ADHD, Sleep
Sleep IntervEntion as Symptom Treatment for ADHD
Up to 72% of adolescents with ADHD portray sleep problems. The most common sleep difficulties in adolescents with ADHD are initial insomnia, nocturnal awakenings, non-restorative or restless sleep.
- Conditions
- ADHD, Sleep, Adolescents, CBT
- Trial name
- SIESTA (NCT04723719)
- Testing
- SIESTA, Treatment as usual for ADHD
- Where
- Belgium
- Volunteers
- 92 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Attention Deficit Hyperactivity Disorder, ADHD
Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD
This multi-center parallel study is designed to study the efficacy and safety of fixed doses of methylphenidate extended release (ER) capsules of four dose levels compared with a placebo group in pediatric patients with Attention…
- Trial name
- NCT01239030
- Testing
- Methylphenidate Hydrochloride Extended Release Capsules
- Where
- 16 sites in United States
- Volunteers
- 230 people
- Sponsor
- Rhodes Pharmaceuticals, L.P.
Attention Deficit Hyperactivity Disorder
An Open-Label Study of Naltrexone in Adults With Attention Deficit Hyperactivity Disorder.
The primary aim of this study is to assess whether naltrexone as a monotherapy is effective in treating Attention Deficit Hyperactivity Disorder (ADHD) in adults.
- Trial name
- NCT01873729
- Testing
- Naltrexone
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Massachusetts General Hospital
ADHD, ADHD - Combined Type
Phase 3 Efficacy and Safety Study in Adults With ADHD Using CTx-1301.
The goal of this clinical trial is to evaluate the efficacy and safety of CTx-1301 in adults with ADHD in a laboratory classroom setting.
- Conditions
- ADHD, ADHD - Combined Type, Attention Deficit Hyperactivity Disorder Combined, Attention Deficit Hyperactivity Disorder
- Trial name
- NCT05631626
- Testing
- CTx-1301 - Dexmethylphenidate 25mg, CTx-1301 - Dexmethylphenidate 37.5mg, CTx-1301 - Dexmethylphenidate 50mg
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Cingulate Therapeutics
Attention Deficit Disorder With Hyperactivity, Cocaine-Related Disorders
Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Studies have shown that individuals with attention deficit hyperactivity disorder (ADHD) are at greater risk for having a substance use disorder compared to people who do not have ADHD.
- Trial name
- Atom (NCT00218543)
- Testing
- Atomoxetine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
ADHD
KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHD
This study is a multicenter, dose-optimized, open-label safety study with KP415 in children with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT03460652
- Testing
- KP415 oral capsule
- Where
- 19 sites in United States
- Volunteers
- 282 people
- Sponsor
- Zevra Therapeutics
Phenylketonuria
Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) Patients
This double-blind, placebo-controlled, randomized study is designed to evaluate the safety and therapeutic effects of sapropterin dihydrochloride on neuropsychiatric symptoms in subjects with PKU.
- Trial name
- NCT01114737
- Testing
- Sapropterin dihydrochloride
- Where
- 36 sites in United States, Canada
- Volunteers
- 206 people
- Sponsor
- BioMarin Pharmaceutical
ADHD
The Reinforcing Mechanisms of Smoking in Adult ADHD
Whereas the smoking prevalence rates in the general population are declining, rates among people diagnosed with attention-deficit hyperactivity disorder (ADHD) continue to be elevated.
- Trial name
- NCT00573859
- Testing
- ADHD medication
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of California, Irvine
Marijuana Abuse, Attention Deficit Disorder With Hyperactivity
Atomoxetine Treatment for ADHD and Marijuana Dependence
The aim of the study is to determine if atomoxetine treatment combined with motivational enhancement therapy is effective in reducing marijuana use in adult individuals with attention-deficit hyperactivity disorder and marijuana…
- Trial name
- NCT00360269
- Testing
- Atomoxetine, Motivational enhancement therapy
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Medical University of South Carolina
Attention Deficit Hyperactivity Disorder
Gene-environment Interactions and Brain Functional Connectivity in Attention Deficit Hyperactivity Disorder
The aims of the current study are to examine gene-environment interactions associated with norepinephrine (NE) system genes (ADRA2A, SLC6A2) in ADHD, and to evaluate whether genetic changes in norepinephrine pathway are…
- Trial name
- NCT01912352
- Testing
- Methylphenidate
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Seoul National University
ADHD
Clinical Efficacy & Safety, of Metadoxine (MG01CI) Extended Release in Attention-Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate efficacy, safety and tolerability of metadoxine (MG01CI) extended release formulation for the treatment of adults diagnosed with ADHD
- Trial name
- NCT01243242
- Testing
- Metadoxine (MG01CI)
- Where
- 2 sites in Israel
- Volunteers
- 120 people
- Sponsor
- Alcobra Ltd.
Attention Deficit Disorder With Hyperactivity
Behavioral Treatment, Drug Treatment, and Combined Treatment for Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to determine the effectiveness of behavioral treatment, drug treatment, and combined treatment for children with Attention Deficit Hyperactivity Disorder (ADHD).
- Trial name
- NCT00050622
- Testing
- Methylphenidate 0.15 mg/kg, Low-Intensity BMOD, Methylphenidate 0.3 mg/kg
- Where
- 2 sites in United States
- Volunteers
- 154 people
- Sponsor
- Florida International University
ADHD
Double-blind, Placebo-controlled, Randomised Withdrawal, Extension, Safety and Efficacy Study of LDX in Children and Adolescents Aged 6-17
The main aim of this study is to evaluate the long-term maintenance of efficacy of LDX after administered to children and adolescents aged 6-17 with ADHD for at least 6 months
- Trial name
- NCT00784654
- Testing
- Lisdexamfetamine dimesylate (LDX)
- Where
- 51 sites in United States, Belgium and 7 more
- Volunteers
- 276 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder
PK/PD Pediatric ADHD Classroom Study
The purpose of this study is to evaluate the association between blood drug levels and the corresponding scores of commonly used behavioral instruments based upon data collected following administration of three different…
- Trial name
- NCT02536105
- Testing
- Methylphenidate HCl ER tablets 1, Methylphenidate HCl ER tablets 2, Methylphenidate HCl ER for suspension
- Where
- 2 sites in United States
- Volunteers
- 88 people
- Sponsor
- Massachusetts General Hospital
Attention Deficit Disorder With Hyperactivity
Efficacy of Lisdexamfetamine Dimesylate for Promoting Occupational Success in Young Adults With ADHD
There has been little research on the third area of impairment noted in the Diagnostic and Statistical Manual of Mental Disorders - "occupational functioning." Individuals with ADHD experience job-related impairments including a…
- Trial name
- NCT03446885
- Testing
- Lisdexamfetamine Dimesylate 40 MG
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Gregory Fabiano
Attention Deficit Hyperactivity Disorder
Skills Training for Adolescents With ADHD
The proposed study will be an initial test of a cognitive-behavioral intervention for adolescents with ADHD who are receiving medication treatment.
- Trial name
- NCT01019252
- Testing
- Cognitive Behavioral Therapy (CBT)
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Massachusetts General Hospital
ADHD
Study to Evaluate NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder (ADHD)
The goal of this clinical trial is to evaluate the efficacy and safety of NRCT-101SR compared to placebo in adult patients with ADHD aged 18 years and older.
- Trial name
- NCT05683249
- Testing
- NRCT-101-SR
- Where
- 9 sites in United States
- Volunteers
- 223 people
- Sponsor
- Neurocentria, Inc.
Attention Deficit Hyperactivity Disorder, Substance Abuse
Atomoxetine for Attention Deficit Hyperactivity Disorder in Adolescents With Substance Use Disorder
The purpose of this study is to find out whether atomoxetine (also called Strattera) helps teenagers (12-19) with Attention Deficit Hyperactivity Disorder (ADHD) and drug/alcohol problems.
- Trial name
- NCT00399763
- Testing
- Atomoxetine
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Denver Health and Hospital Authority
ADHD
PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
This is a randomized, double-blind, parallel group, placebo-controlled, dose optimized, phase 3 study to evaluate the safety and efficacy of PRC-063 in the treatment of ADHD in adults
- Trial name
- NCT03618030
- Testing
- PRC-063 oral capsules
- Where
- 8 sites in United States
- Volunteers
- 288 people
- Sponsor
- Purdue Pharma, Canada
ADHD
Genetic Modulation of Working Memory in Attention Deficit Hyperactivity Disorder (ADHD)
In this study the investigators will measure the functional brain activity of adult Attention Deficit Hyperactivity Disorder (ADHD) patients, genotyped according to the COMT genotype, during a Working Memory Paradigm, before and…
- Trial name
- BEAS (NCT01351272)
- Testing
- Methylphenidate, non-retard
- Where
- Germany
- Volunteers
- 41 people
- Sponsor
- Wuerzburg University Hospital